- Home
- BQ vs VYNE Comparison
BQ vs VYNE Comparison
Compare BQ & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- VYNE
- Stock Information
- Founded
- BQ 2008
- VYNE 2003
- Country
- BQ China
- VYNE United States
- Employees
- BQ N/A
- VYNE N/A
- Industry
- BQ Other Specialty Stores
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- VYNE Health Care
- Exchange
- BQ Nasdaq
- VYNE Nasdaq
- Market Cap
- BQ 7.1M
- VYNE 7.9M
- IPO Year
- BQ 2020
- VYNE 2018
- Fundamental
- Price
- BQ $11.77
- VYNE $0.41
- Analyst Decision
- BQ
- VYNE Buy
- Analyst Count
- BQ 0
- VYNE 2
- Target Price
- BQ N/A
- VYNE $8.00
- AVG Volume (30 Days)
- BQ 3.5M
- VYNE 2.6M
- Earning Date
- BQ 07-21-2025
- VYNE 11-06-2025
- Dividend Yield
- BQ N/A
- VYNE N/A
- EPS Growth
- BQ N/A
- VYNE N/A
- EPS
- BQ N/A
- VYNE N/A
- Revenue
- BQ $64,617,102.00
- VYNE $476,000.00
- Revenue This Year
- BQ N/A
- VYNE N/A
- Revenue Next Year
- BQ N/A
- VYNE N/A
- P/E Ratio
- BQ N/A
- VYNE N/A
- Revenue Growth
- BQ N/A
- VYNE N/A
- 52 Week Low
- BQ $1.62
- VYNE $0.28
- 52 Week High
- BQ $46.70
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BQ 67.27
- VYNE 57.89
- Support Level
- BQ $8.75
- VYNE $0.32
- Resistance Level
- BQ $24.00
- VYNE $0.35
- Average True Range (ATR)
- BQ 5.77
- VYNE 0.02
- MACD
- BQ 1.02
- VYNE 0.02
- Stochastic Oscillator
- BQ 19.89
- VYNE 92.82
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.